ABSTRACT
The article deals the modern concepts of the mechanism of pain in osteoarthritis. It was established that synovial inflammation and immune disorders play an important role in the pathogenesis of pain in osteoarthritis. Hyperproduction of pro-inflammatory cytokines supports inflammation and degradation of cartilaginous tissue in osteoarthritis. The mechanisms of pathogenetic action of chondroitin sulfate are disclosed, and the evidence base of its preclinical and clinical studies in the treatment of osteoarthritis is presented. The data of clinical application of the Mucosat - pharmaceutical substance chondroitin sulfate in the form of a ready-made dosage form for intramuscular injection are presented. The practical advantages of including SYSADOA in complex therapy of osteoarthritis are discussed.
Subject(s)
Arthralgia , Chondroitin Sulfates , Osteoarthritis , Arthralgia/drug therapy , Arthralgia/etiology , Chondroitin Sulfates/metabolism , Chondroitin Sulfates/pharmacology , Humans , Injections, Intramuscular , Osteoarthritis/diagnosis , Osteoarthritis/drug therapy , Osteoarthritis/metabolism , Pain Management/methods , Protective Agents/pharmacology , Treatment OutcomeABSTRACT
This study was designed to analyze results of daptomycin therapy in 7 patients with enterococcal infectious endocarditis caused by Enterococcus faecium in two of them. Mean duration of therapy was 36.7 days. 70% of the strains proved resistant to gentamycin, 40% showed resistance to penicillin antibiotics, and 14.3% to vancomycin. Three patients suffered prosthetic valve endocarditis, six had elevated presepsin level (up to 768.8 pg/ml). 28,6% of the patients underwent valve prosthetic surgery. Hospital lethality was 14,3%. The effectiveness of ampicillin plus ceftriaxone treatment of gentanycin-resistant enterococci is discussed. Recommendation for the antibacterial treatment of enterococcal infectious endocarditis (ESC 2015) are provided.
Subject(s)
Daptomycin/administration & dosage , Endocarditis, Bacterial , Enterococcus faecium , Gram-Positive Bacterial Infections , Anti-Bacterial Agents/administration & dosage , Echocardiography/methods , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/mortality , Endocarditis, Bacterial/therapy , Enterococcus faecium/drug effects , Enterococcus faecium/isolation & purification , Female , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Gram-Positive Bacterial Infections/therapy , Heart Valve Prosthesis/microbiology , Heart Valves/microbiology , Humans , Male , Middle Aged , Russia/epidemiology , Survival Analysis , Treatment OutcomeABSTRACT
A case of retroperitoneal fibrosis (Ormond's disease) is reported. It is known to be usually diagnosed at the late stages of renal complications Urinary infection ended in infectious endocarditis caused by E. faecium showing multiple resistance to antibiotics. Moderate immunosuppressive and modern antibacterial (daptomycin) therapy ensured remission of both Ormond's diseases and endocarditis.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Brain Infarction , Craniotomy/methods , Daptomycin/administration & dosage , Hydronephrosis , Immunosuppressive Agents/administration & dosage , Methylprednisolone/administration & dosage , Retroperitoneal Fibrosis , Adult , Anti-Inflammatory Agents/administration & dosage , Brain Infarction/diagnosis , Brain Infarction/etiology , Brain Infarction/physiopathology , Brain Infarction/surgery , Enterococcus faecium/isolation & purification , Female , Humans , Hydronephrosis/diagnosis , Hydronephrosis/etiology , Hydronephrosis/physiopathology , Hydronephrosis/therapy , Laparotomy/methods , Retroperitoneal Fibrosis/complications , Retroperitoneal Fibrosis/diagnosis , Retroperitoneal Fibrosis/physiopathology , Retroperitoneal Fibrosis/therapy , Retroperitoneal Space/pathology , Tomography, X-Ray Computed , Treatment Outcome , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Urinary Tract Infections/physiopathologyABSTRACT
We compared the efficacy of recombinant infliximab and adalimumab in patients with severe and moderately severe rheumatoid arthritis. Infliximab produced rapid anti-inflammatory effect in the early period of therapy whereas adalimumab ensured more stable reduction of clinical and laboratory parameters of activity.